Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108639 · ClinicalTrials.gov registry record · Phase 1
To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT02108639 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 41 participants.
The verdict
NCT02108639, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Assess the effect of renal function on the blood levels of DCV, ASV, BMS-791325.
Interventions
- DRUG BMS-791325
- DRUG DCV 3DAA FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02108639
The ClinicalTrials.gov registry entry for NCT02108639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-791325 is the first listed.
NCT02108639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02108639 about?
NCT02108639 is a clinical study titled "To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet". Assess the effect of renal function on the blood levels of DCV, ASV, BMS-791325.
What is the current status of trial NCT02108639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2014-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02108639?
The interventions under investigation include: BMS-791325 (DRUG), DCV 3DAA FDC (DRUG).
Who is sponsoring clinical trial NCT02108639?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.